<DOC>
	<DOC>NCT01338545</DOC>
	<brief_summary>This observational study will evaluate the dosage patterns, safety and efficacy of RoActemra/Actemra (tocilizumab) in clinical practice in patients with moderate to severe rheumatoid arthritis who have not responded or are intolerant to at least one disease-modifying antirheumatic drug (DMARD) or TNF inhibitor. Data will be collected from each patients for 12 months.</brief_summary>
	<brief_title>An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Moderate to severe rheumatoid arthritis (RA) of at least 6 months duration Nonresponder or intolerant to at least one DMARD or TNF inhibitor treatment Initiated on treatment with RoActemra according to Summary of Product Characteristics (SPC) indications History of autoimmune disease or of any joint inflammatory disease other than RA Pregnant or lactating women Patients who have started RoActemra treatment in a clinical trial or for compassionate use Treatment with any investigational drug in the previous 4 weeks (or at least 5 times the halflife of the drug)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>